Key result
Tailoring the duration of vitamin K antagonist treatment after deep vein thrombosis based on residual vein thrombosis and D-dimer levels may optimize management of recurrent thrombosis risk.
Why the study?
Does tailoring the length of vitamin K antagonist treatment based on residual vein thrombosis and D-dimer levels improve outcomes in patients with a first episode of proximal deep vein thrombosis?
Does tailoring the length of vitamin K antagonist treatment based on residual vein thrombosis and D-dimer levels improve outcomes in patients with a first episode of proximal deep vein thrombosis?
Tailoring the duration of anticoagulation after a first DVT using parameters like residual vein thrombosis and D-dimer levels may optimize treatment by balancing the risks of recurrence and bleeding.
Answers are grounded in this paper and cite their sources.
Should not yet alter vitamin K antagonist duration after deep vein thrombosis; leaves open prospective validation of residual vein thrombosis and D-dimer tailoring.
The current approach for deciding the duration of vitamin K antagonist (VKA) treatment after an episode of venous thrombo-embolism (VTE) is mainly based on the characteristic of the index event (3 months or longer in case of unknown/persistent risk factors, 3 months or less in case of removable causes). However, the length of anticoagulation should be tailored on the patient's risk for recurrent thrombosis as well as for bleeding, but such 'time for decision' is often unclear and the optimal duration of VKA remains debatable. The presence of persistent residual vein thrombosis and increased D-dimer levels after stopping therapy are predictors for recurrent deep vein thrombosis (DVT). Management strategies based on these parameters have been demonstrated to optimize the decision for VKA duration, as they establish the patient's intrinsic risk for recurrent events. This annotation discusses current practice and upcoming approaches regarding the length of VKA treatment after a first episode of DVT.
No takes yet. Share an insight, caveat, or question.
Siragusa et al. (2009) conducted a review in Proximal deep vein thrombosis / Venous thrombo-embolism. Vitamin K antagonist (VKA) treatment duration was evaluated. Tailoring the duration of vitamin K antagonist treatment after deep vein thrombosis based on residual vein thrombosis and D-dimer levels may optimize management of recurrent thrombosis risk.
Synapse has enriched 10 related papers. Consider them for comparative context: